Cancer Research and Treatment

The Effect of Neoadjuvant Chemotherapy with 5-Fluorouracil (5-FU), Vinblastine and Cisplatin (FVP) for Stage III Non-Small Cell Lung Cancer (NSCLC): Jung Il Won, Jong Ho Chun, Hyeong Jun Kim, Moon Suk Jo, Dong Kyu Kim, Young Tae Kwak, Jung Suk Kim, Soo Jeon Choi, Sung Rok Kim; J Korean Cancer Assoc. 1997;29(5):807-815.

Abstract PDF: PURPOSE
As the prognosis of stage III NSCLC is still poor with or without operation, we conducted a phase II trial of neoadjuvant chemotherapy (CHT) with 5-FU, vinblastine, cisplatin prior to surgery to determine the effect on resectability and survival.
MATERIALS AND METHOD
Patients (pt) received 5-FU 500mg/m2/12 hours continuous infusion for 36 hours, vinblastine 3mg/m2/day iv bolus day 1 and day 2, and cisplatin 75mg/m2 iv day 1 every 3 weeks. This regimen was given for 2 cycles. When the tumor was responsive (stable disease or better), 1 or 2 more cycles of the CHT were given, followed by operation when totally resectable on chest CT/MRI, then 3 more cycles of the CHT to finish the treatment; when the tumor was neither responsive nor resectable after 3rd or 4th CHT, radiotherapy was started.
RESULT
Twenty nine pt were enrolled and 26 pt have been evaluable so far. Age ranged from 32 to 79 (median 59 years); 23 were male, 3 female. Total of 108 cycles were given (mean 4.2). There were 4 partial remissions out of 6 IIIAs (67%) and 10 out of 20 IIIBs (50%), with overall response rate of 53.8%; down staging was noted in 9 patients (34.6%). 9 pt (34.6%) underwent curative resection successfully; 4 out of 6 IIIAs (67%) and 5 out of 20 IIIBs (25.0%); 1 patient refused operation. Median survival was 31.3 months for 9 pt with operation, and that of all patients was 14.2 months. Radiation was given to 9 pt, resulting in 3 partial remissions (PR), 3 stable diseases (SD), 3 progressive diseases (PD). Serious (WHO grade> or =3) toxicities were nausea/emesis in 2.8%, granulocytopenia in 26.9% and thrombocytopenia in 2.8%.
CONCLUSION
This treatment modality seemed to be effective, encouraging further phase III study for better determination of its role.

2,781 View
15 Download

Serious Toxicities Induced by Vinblastine Overdose in a Patient with Relapsed Hodgkin's Disease: Sang Kook Han, Yong Joo Kim, Ji Youn Han, Jin Hyoung Kang, Han Lim Moon, Young Seon Hong, Hoon Kyo Kim, Kyung Shik Lee, Dong Jip Kim; J Korean Cancer Assoc. 1994;26(5):841-847.

Abstract PDF: Vinblastine, referred to as a vinka alkaloid, has been used as a component of the various chemotherapeutic regimens in the treatment of nonseminomatous testicular carcinoma, chorioearcinoma, non-small cell lung carcinoma, bladder cancer, head and neck cancer and cervical cancer. Vinblastine has been used as a main component of ABVD combination therapy for the patients with advanced Hodgkins disease who relapsed after therapy with the MOPP regimen. The major adverse effects of usual dosage of vinblatine are myelosuppression, nausea, vomiting, local effects(phlebitis, necrosis when extravasated), and peripheral and autonomic neuropathies. We experienced the life threatening toxicities including bone marrow suppression, oral mucositis, peripheral neuropathies and paralytic ileus in a 41-year-old male patient with re- lapsed Hodgkins disease who was errorneously treated with 50 mg of vinblastine. The patient was recovered completely with intensive supportive treatment.

2,478 View
20 Download

VP-16 and Cisplatin Combination Chemotherapy in Small Cell Lung Cancer: Jae Seok Kim, Hyuk Chan Kwon, Sung Jin Bae, Myung Hwan Noh, Won Tae Chung, Hyo Jin Kim, Chang Woon Kang, Jong Seong Kim; J Korean Cancer Assoc. 1995;27(1):77-84.

Abstract PDF: Objectives
Despite recent advances in chemotherapy, the treatment outcome of advanced non-small cell lung cancer(NSCLC) remains poor and NSCLC is still the predominant source of cancer-related mortality in worldwide. Thus, we evaluated the efficacy and safety of a combination chemotherapy with mitomycin C, vinblastine, and cisplatin(MVP) in advanced NSCLC patients in Korea. Methods; Cisplatin was infused intravenously at a dose 20 mg/m from 1st to 5th day and mitomycin C 10 mg/m and vinblastine 6 mg/m were given intravenously on day 1. This treatment schedule was repeated every 3 weeks. Results: Among 94 evaluable patients, overall response rate was 44% including 4% of complete response. Squamous cell carcinoma responded better than adenocarcinoma. The median time to progression was 24 weeks and the median survival time was 42 weeks. Statistically significant survival advantage was observed in responder group(60 weeks vs. 36 weeks). The toxicities of this regimen were mild and well tolerated. Conclusion: In advanced NSCLC, MVP combination chemotherapy is relatively effective and safe.

3,165 View
16 Download

The Effect of Combination Chemotherapy with Mitomycin C , Vinblastine , and Cisplatin ( MVP ) in Pastients with Advanced Non - Small Cell Lung Cancer: Sang Goo Lee, Young Hyuck Im, Choon Taek Lee, Hyung Gun Kim, Tae Young Son, Young Jin Yuh, Eun Mee Cheon, Yoon Koo Kang, Young Whang Kim, Jhin Oh Lee, Tae Woong Kang; J Korean Cancer Assoc. 1995;27(1):84-92.

PDF

2,994 View
22 Download

Search